Kymera Therapeutics, Inc.
KYMR
$81.21
$1.612.02%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -39.08% | -76.22% | -74.49% | -55.82% | -52.32% |
| Total Depreciation and Amortization | 12.75% | 31.72% | 56.34% | 91.95% | 106.82% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 19.43% | 17.65% | 5.90% | 0.44% | 21.29% |
| Change in Net Operating Assets | 163.69% | 169.46% | -1,407.72% | -639.06% | -993.74% |
| Cash from Operations | -19.74% | -82.82% | -136.51% | -137.75% | -89.16% |
| Capital Expenditure | 88.71% | 90.31% | 94.00% | 84.41% | 62.77% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -32.81% | 87.02% | 110.52% | 89.32% | -324.38% |
| Cash from Investing | -28.95% | 87.20% | 108.29% | 88.46% | -388.86% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 5.20% | -282.96% | -2,694.74% | -3,907.69% | -1,973.68% |
| Issuance of Common Stock | 63.45% | -47.73% | 48.37% | -20.05% | 14,866.96% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -82.98% | -- | -- | -- | -- |
| Cash from Financing | 62.72% | -52.59% | 40.00% | -28.43% | 14,424.12% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 2,204.69% | -92.46% | 1,656.85% | -108.28% | -75.10% |